A Telephone-Based Prevention Care Manager in Increasing Screening Rates for Breast Cancer, Cervical Cancer, and Colorectal Cancer in Minority and Low-Income Women

NCT ID: NCT00376909

Last Updated: 2014-12-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

2729 participants

Study Classification

INTERVENTIONAL

Study Start Date

2001-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: Studying the barriers that prevent minority and low-income women from undergoing cancer screening, and offering encouragement to them over the telephone, may help improve cancer screening rates.

PURPOSE: This randomized phase II trial is studying how well a telephone-based Prevention Care Manager increases screening rates for breast cancer, cervical cancer, and colorectal cancer in minority and low-income women.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES:

* Determine whether telephone support for patients, provided through a Prevention Care Manager (PCM), can increase breast, cervical, and colorectal cancer screening rates among minority and low-income women.
* Measure the amount of PCM time required to improve early cancer detection provided to age-eligible ethnically diverse women seen in community health centers in the New York City area.
* Learn barriers faced by this population in obtaining indicated services (mammograms, Pap tests, fecal occult blood testing, and sigmoidoscopy).
* Assess at baseline and follow-up the office environment and work processes in each participating center (in PCM randomized controlled study only).
* Develop and implement the PCM intervention to help patients overcome barriers.
* Evaluate the impact and costs of the PCM in a randomized controlled efficacy trial.

OUTLINE: This is a randomized, controlled, single-blind, multicenter study. Patients are randomized according to participating center.

* Part 1: Some patients undergo a series of structured interviews about the obstacles to early cancer detection. Participating sites are assessed for study eligibility.
* Part 2: Pilot testing, training, and competency testing of the Prevention Care Managers (PCM) are conducted.
* Part 3: Patients are randomized to 1 of 2 intervention arms.

* Arm I: Patients are offered health education and follow-up services by telephone with a PCM.
* Arm II: Patients receive usual care.

PROJECTED ACCRUAL: A total of 2,729 (1,413 for PCM randomized controlled study and 1,316 for pilot study) patients will be accrued for this study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer Cervical Cancer Colorectal Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

SCREENING

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention

Series of telephone support calls from a trained prevention care manager

Group Type EXPERIMENTAL

educational intervention

Intervention Type OTHER

study of socioeconomic and demographic variables

Intervention Type OTHER

Usual Care

Usual care

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

educational intervention

Intervention Type OTHER

study of socioeconomic and demographic variables

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

DISEASE CHARACTERISTICS:

* Patients enrolled in the Prevention Care Manager (PCM) controlled, randomized clinical trial (RCT) must meet the following criteria:

* Registered to receive care at a participating Community Health Center for at least 6 months
* Overdue for at least one cancer screening as per the following time periods:

* No mammography within the past 12 months
* No Pap test within the past 12 months
* No home fecal occult blood test within the past 12 months
* No sigmoidoscopy within the past 5 years
* No colonoscopy within the past 10 years
* Must not plan to move out of area or change Community Health Center within 15 months
* No unresolved, urgent abnormal cancer screening result found in medical record
* Patients enrolled in the PCM dissemination pilot study through Affinity Health Plan must meet the following criteria:

* Enrolled with Affinity Health Plan for at least 12 months
* Overdue for at least one cancer screening as per the following time periods:

* No mammography within the past 2 years
* No Pap test within the past 3 years
* No home fecal occult blood test within the past year for women ≥ 50 years old
* No sigmoidoscopy within the past 5 years
* No colonoscopy within the past 10 years
* Must have received care at 1 of 6 participating Community Health Centers in New York City

PATIENT CHARACTERISTICS:

* Female
* Must not be in acute distress or have an acute illness
* Age 50 to 69 years for controlled study patients
* Age 40 to 69 years for pilot study patients

PRIOR CONCURRENT THERAPY:

* No concurrent chemotherapy or radiotherapy
* No concurrent active cancer treatment
* No concurrent palliative care
Minimum Eligible Age

40 Years

Maximum Eligible Age

69 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Cancer Institute (NCI)

NIH

Sponsor Role collaborator

Dartmouth-Hitchcock Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Allen J. Dietrich, MD

Role: PRINCIPAL_INVESTIGATOR

Norris Cotton Cancer Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center

Lebanon, New Hampshire, United States

Site Status

Clinical Directors Network, Incorporated

New York, New York, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Dietrich AJ, Tobin JN, Cassells A, Robinson CM, Greene MA, Sox CH, Beach ML, DuHamel KN, Younge RG. Telephone care management to improve cancer screening among low-income women: a randomized, controlled trial. Ann Intern Med. 2006 Apr 18;144(8):563-71. doi: 10.7326/0003-4819-144-8-200604180-00006.

Reference Type RESULT
PMID: 16618953 (View on PubMed)

Dietrich AJ, Tobin JN, Cassells A, Robinson CM, Reh M, Romero KA, Flood AB, Beach ML. Translation of an efficacious cancer-screening intervention to women enrolled in a Medicaid managed care organization. Ann Fam Med. 2007 Jul-Aug;5(4):320-7. doi: 10.1370/afm.701.

Reference Type RESULT
PMID: 17664498 (View on PubMed)

Ogedegbe G, Cassells AN, Robinson CM, DuHamel K, Tobin JN, Sox CH, Dietrich AJ. Perceptions of barriers and facilitators of cancer early detection among low-income minority women in community health centers. J Natl Med Assoc. 2005 Feb;97(2):162-70.

Reference Type RESULT
PMID: 15712779 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

R01CA087776

Identifier Type: NIH

Identifier Source: secondary_id

View Link

DMS-15524

Identifier Type: -

Identifier Source: secondary_id

CDR0000450797

Identifier Type: -

Identifier Source: org_study_id